HUP0103797A2 - TPL-2/COT kináz és alkalmazásai - Google Patents
TPL-2/COT kináz és alkalmazásaiInfo
- Publication number
- HUP0103797A2 HUP0103797A2 HU0103797A HUP0103797A HUP0103797A2 HU P0103797 A2 HUP0103797 A2 HU P0103797A2 HU 0103797 A HU0103797 A HU 0103797A HU P0103797 A HUP0103797 A HU P0103797A HU P0103797 A2 HUP0103797 A2 HU P0103797A2
- Authority
- HU
- Hungary
- Prior art keywords
- tpl
- compounds
- methods
- nfkb
- activation
- Prior art date
Links
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 abstract 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000004913 activation Effects 0.000 abstract 2
- 230000028709 inflammatory response Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
Abstract
A találmány szerint a TPL-2 felelős a p105 foszforilációjáért és azebből következő proteolízisért, amely a p50 Rel sejtmagba valóáthelyődését eredményezi. A találmány tehát a TPL-2-t, mint az NFkBaktiválódás specifikus regulátorát és ennélfogva azon inflammatórikusválaszok modulátoraként ismerteti, amelyekben a p105 vesz részt. Atalálmány szerint a TPL-2 eszközül szolgál olyan vegyületekkifejlesztésében, amelyek képesek befolyásolni az NFkB aktiválódását.Ismertetik továbbá ezen vegyületek azonosítására szolgáló eljárásokatés az ilyen módon azonosított vegyületek olyan betegségek kezelésébenvaló alkalmazását javasolják, amelyek inflammatórikus válasz váltanakki. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9817930.2A GB9817930D0 (en) | 1998-08-18 | 1998-08-18 | Pathway |
GBGB9827712.2A GB9827712D0 (en) | 1998-12-16 | 1998-12-16 | Pathway |
PCT/US1999/018543 WO2000011191A2 (en) | 1998-08-18 | 1999-08-13 | Tpl-2/cot kinase and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0103797A2 true HUP0103797A2 (hu) | 2003-10-28 |
Family
ID=26314223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0103797A HUP0103797A2 (hu) | 1998-08-18 | 1999-08-13 | TPL-2/COT kináz és alkalmazásai |
Country Status (22)
Country | Link |
---|---|
US (1) | US20020099169A1 (hu) |
EP (1) | EP1105501A2 (hu) |
JP (1) | JP4719831B2 (hu) |
KR (1) | KR20010085407A (hu) |
CN (1) | CN1323346A (hu) |
AU (1) | AU767973B2 (hu) |
BG (1) | BG105345A (hu) |
BR (1) | BR9913070A (hu) |
CA (1) | CA2339036A1 (hu) |
CZ (1) | CZ2001625A3 (hu) |
HK (1) | HK1041901A1 (hu) |
HU (1) | HUP0103797A2 (hu) |
ID (1) | ID28955A (hu) |
IL (1) | IL141355A0 (hu) |
MX (1) | MXPA01001747A (hu) |
NO (1) | NO20010786L (hu) |
NZ (1) | NZ510313A (hu) |
PL (1) | PL347137A1 (hu) |
RU (1) | RU2001107122A (hu) |
SK (1) | SK2242001A3 (hu) |
TR (2) | TR200103840T2 (hu) |
WO (1) | WO2000011191A2 (hu) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660906B1 (en) | 2000-03-08 | 2003-12-09 | Thomas Jefferson University | Tpl2 transgenic knockout mice |
US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
GB0402661D0 (en) * | 2004-02-06 | 2004-03-10 | Medical Res Council | TPL2 and its expression |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
UA71889C2 (uk) * | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
-
1999
- 1999-08-13 KR KR1020017002091A patent/KR20010085407A/ko active IP Right Grant
- 1999-08-13 US US09/374,579 patent/US20020099169A1/en not_active Abandoned
- 1999-08-13 MX MXPA01001747A patent/MXPA01001747A/es unknown
- 1999-08-13 CZ CZ2001625A patent/CZ2001625A3/cs unknown
- 1999-08-13 PL PL99347137A patent/PL347137A1/xx not_active IP Right Cessation
- 1999-08-13 IL IL14135599A patent/IL141355A0/xx unknown
- 1999-08-13 NZ NZ510313A patent/NZ510313A/en unknown
- 1999-08-13 TR TR2001/03840T patent/TR200103840T2/xx unknown
- 1999-08-13 BR BR9913070-0A patent/BR9913070A/pt not_active IP Right Cessation
- 1999-08-13 CN CN99812172A patent/CN1323346A/zh active Pending
- 1999-08-13 ID IDW20010645A patent/ID28955A/id unknown
- 1999-08-13 AU AU55633/99A patent/AU767973B2/en not_active Ceased
- 1999-08-13 WO PCT/US1999/018543 patent/WO2000011191A2/en not_active Application Discontinuation
- 1999-08-13 TR TR2001/00624T patent/TR200100624T2/xx unknown
- 1999-08-13 EP EP99942203A patent/EP1105501A2/en not_active Withdrawn
- 1999-08-13 JP JP2000566444A patent/JP4719831B2/ja not_active Expired - Fee Related
- 1999-08-13 CA CA002339036A patent/CA2339036A1/en not_active Abandoned
- 1999-08-13 HU HU0103797A patent/HUP0103797A2/hu unknown
- 1999-08-13 RU RU2001107122/14A patent/RU2001107122A/ru not_active Application Discontinuation
- 1999-08-13 SK SK224-2001A patent/SK2242001A3/sk unknown
-
2001
- 2001-02-16 NO NO20010786A patent/NO20010786L/no not_active Application Discontinuation
- 2001-03-15 BG BG105345A patent/BG105345A/xx unknown
-
2002
- 2002-05-14 HK HK02103643.3A patent/HK1041901A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CZ2001625A3 (cs) | 2002-02-13 |
HK1041901A1 (zh) | 2002-07-26 |
KR20010085407A (ko) | 2001-09-07 |
EP1105501A2 (en) | 2001-06-13 |
MXPA01001747A (es) | 2003-06-06 |
CA2339036A1 (en) | 2000-03-02 |
IL141355A0 (en) | 2002-03-10 |
ID28955A (id) | 2001-07-19 |
BR9913070A (pt) | 2001-05-08 |
US20020099169A1 (en) | 2002-07-25 |
TR200103840T2 (tr) | 2002-06-21 |
WO2000011191A2 (en) | 2000-03-02 |
RU2001107122A (ru) | 2003-04-20 |
CN1323346A (zh) | 2001-11-21 |
AU767973B2 (en) | 2003-11-27 |
WO2000011191A3 (en) | 2000-06-08 |
PL347137A1 (en) | 2002-03-25 |
NO20010786D0 (no) | 2001-02-16 |
TR200100624T2 (tr) | 2001-08-21 |
JP4719831B2 (ja) | 2011-07-06 |
AU5563399A (en) | 2000-03-14 |
NO20010786L (no) | 2001-04-17 |
SK2242001A3 (en) | 2001-10-08 |
JP2002531058A (ja) | 2002-09-24 |
BG105345A (en) | 2001-12-31 |
NZ510313A (en) | 2003-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
DE602004019812D1 (de) | Marker für neuromyelitis optica | |
BRPI0514395A (pt) | uso terapêutico de inibidores de rtp801 | |
AR004717A1 (es) | Sal de bis-indolilmaleimida, formulacion farmaceutica que la comprende y su uso para la fabricacion de dicha formulacion | |
MXPA04000062A (es) | Miembros de drenaje extensibles para conectar a tierra la proteccion por interferencia electromagnetica/interferencia por radiofrecuencia. | |
BR0112644A (pt) | Método de identificar marcadores de câncer e usos destes no diagnóstico do câncer | |
HUP0302384A2 (hu) | Sejtek bioenergia metabolizmusában szerepet játszó biokémiai vegyületeket tartalmazó készítmények és alkalmazásuk | |
HUP0103797A2 (hu) | TPL-2/COT kináz és alkalmazásai | |
AU2374302A (en) | Means for detecting pathological transformation of the app protein and their uses | |
DE69920487D1 (de) | Tau als marker für frühe schäden des zentralen nervensystems | |
AU2003233715A1 (en) | Use of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease | |
WO2003063059A3 (en) | Method for positively identifying livestock and use thereof in legal instruments relating thereto | |
DE69625099D1 (de) | Vorrichtung für einen Ringkammerofen | |
PT1435521E (pt) | Detecção e diagnóstico de encefalopatias espongiformes transmissíveis | |
WO2003036261A3 (en) | Drug development by rapid neuroimaging of neural cells | |
BR0313230A (pt) | Uso de carboxamidas para o tratamento de tinido | |
PT1133295E (pt) | Utilizacao da nicergolina no tratamento da espasticidade | |
ATE360094T1 (de) | Tcf-1 nukleotidsequenzvariation | |
WO2001097607A3 (en) | Transgenic animal model of neurodegenerative disorders | |
ATE315901T1 (de) | Sprungfedermatratze | |
GEP20074101B (en) | Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases | |
WO2002036166A3 (en) | Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease | |
BR0215452A (pt) | Teste de proteìna tirosina-fosfatase (ptpase) altamente sensitivo com o emprego de 6,8-diflúor-4-metil-umbeliferilfosfato | |
BR0309177A (pt) | Sistema e método de avaliação para determinação do impacto de uma modificação na composição nutricional de um ingrediente ou do impacto de um ingrediente novo sobre o valor do ingrediente e o valor de ingredientes competitivos | |
BRPI0413610A (pt) | método para a identificação de agonistas ou inibidores da proteìna quinase irs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |